Date | Price Target | Rating | Analyst |
---|---|---|---|
9/15/2021 | $11.00 | Buy | Maxim Group |
PALO ALTO, Calif., Sept. 12, 2024 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. ("180" or the "Company") is pleased to announce the appointment of Omar Jimenez as its new Chief Financial Officer, effective September 30, 2024. Mr. Jimenez, already a director of the Company, will play a key role in driving the financial strategy of the Company as it continues to grow and innovate in the pharma and biotechnology sectors. "We are excited to have Omar stepping onto our executive team," said Mr. Blair Jordan, CEO of 180. "His extensive financial expertise, combined with his forward-thinking approach, makes him the ideal CFO to guide us through this exciting chapter of growth and transformation fo
PALO ALTO, Calif., July 30, 2024 (GLOBE NEWSWIRE) -- PALO ALTO, Calif., July 30, 2024 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ:ATNF) ("180 Life Sciences" or the "Company"), today announced topline results from a clinical pharmacology study (the "Study"), that evaluated the uptake of cannabidiol (CBD) in a solid formulation which can be delivered as a pill orally. The clinical trial in humans, performed with Prof. Avi Domb of the Hebrew University, School of Pharmacy, and with Prof. Elyad Davidson, of Hadassah Hospital, compared two solid formulations of CBD with a U.S. Food and Drug Administration (FDA) approved drug for epilepsy, Epidiolex. The purpose of the Study was to compa
PALO ALTO, Calif., July 23, 2024 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ:ATNF) ("180 Life Sciences" or the "Company"), today announced that it received notice from the Nasdaq Listing Qualifications Panel (the "Hearings Panel") of The Nasdaq Stock Market LLC ("Nasdaq") that the Hearings Panel has granted the Company's request for additional time to achieve compliance with Nasdaq's continued listing rules and demonstrate long-term compliance with the Equity Rule (defined below). Specifically, the Hearings Panel has agreed to provide the Company until September 20, 2024 to regain compliance with the Equity Rule and to allow the continued listing of the Company's common stock and w
S-1/A - 180 Life Sciences Corp. (0001690080) (Filer)
8-K - 180 Life Sciences Corp. (0001690080) (Filer)
8-K - 180 Life Sciences Corp. (0001690080) (Filer)
SC 13G - 180 Life Sciences Corp. (0001690080) (Subject)
SC 13D/A - 180 Life Sciences Corp. (0001690080) (Subject)
SC 13G/A - 180 Life Sciences Corp. (0001690080) (Subject)
PALO ALTO, Calif., Sept. 12, 2024 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. ("180" or the "Company") is pleased to announce the appointment of Omar Jimenez as its new Chief Financial Officer, effective September 30, 2024. Mr. Jimenez, already a director of the Company, will play a key role in driving the financial strategy of the Company as it continues to grow and innovate in the pharma and biotechnology sectors. "We are excited to have Omar stepping onto our executive team," said Mr. Blair Jordan, CEO of 180. "His extensive financial expertise, combined with his forward-thinking approach, makes him the ideal CFO to guide us through this exciting chapter of growth and transformation fo
Pam Marrone joins as Chairwoman of the Board of Directors and Johan de Saegher as Independent Board Member Elicit Plant, an agricultural biotechnology company specialized in crops' resistance to water stress based on a phytosterol-based technology platform, announced today it has appointed Dr. Pam Marrone as Chairwoman of the Board of Directors and Dr. Johan de Saegher as Independent Board Member. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230301005582/en/Pam Marrone and Johan de Saegher join Elicit Plant's Board of Directors (Photo: Elicit Plant) Pam is a serial entrepreneur bringing over 30 years of leadership experience
PALO ALTO, Calif., Nov. 03, 2021 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ:ATNF) ("180 Life Sciences" or the "Company"), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, today announced the appointment of Quan A. Vu to the role of Chief Operating Officer/Chief Business Officer. Mr. Vu is a highly versatile and accomplished strategy, corporate/business development, finance and operations executive with 20 years of "hands-on" biopharma experience. He is known as a consummate dealmaker with a demonstrated history of prospecting, evaluating, structuring and closing transactions th
3 - 180 Life Sciences Corp. (0001690080) (Issuer)
3 - 180 Life Sciences Corp. (0001690080) (Issuer)
3 - 180 Life Sciences Corp. (0001690080) (Issuer)
180 Life Sciences Corp. (NASDAQ:ATNF) ("180 Life Sciences" or the "Company"), today announced that it received notice from the Nasdaq Listing Qualifications Panel (the "Hearings Panel") of The Nasdaq Stock Market LLC ("Nasdaq") that the Hearings Panel has granted the Company's request for additional time to achieve compliance with Nasdaq's continued listing rules and demonstrate long-term compliance with the Equity Rule (defined below). Specifically, the Hearings Panel has agreed to provide the Company until September 20, 2024 to regain compliance with the Equity Rule and to allow the continued listing of the Company's common stock and warrants on The Nasdaq Stock Market through such date, s
- SEC Filing
Gainers Mustang Bio (NASDAQ:MBIO) stock moved upwards by 307.9% to $0.53 during Monday's regular session. The company's market cap stands at $14.9 million. Scinai Immunotherapeutics (NASDAQ:SCNI) stock moved upwards by 62.17% to $5.66. The company's market cap stands at $3.2 million. ENDRA Life Sciences (NASDAQ:NDRA) shares increased by 32.33% to $0.14. The market value of their outstanding shares is at $2.3 million. Trxade Health (NASDAQ:MEDS) stock increased by 31.87% to $8.7. The company's market cap stands at $12.2 million. 180 Life Sciences (NASDAQ:ATNF) stock increased by 24.11% to $1.92. The company's market cap stands at $1.8 million. Mirum Pharmaceuticals (NASDAQ:MIRM) shares
Maxim Group initiated coverage of 180 Life Sciences Corp. with a rating of Buy and set a new price target of $11.00
4 - 180 Life Sciences Corp. (0001690080) (Issuer)